188 related articles for article (PubMed ID: 12493166)
41. Comparison of Streptococcus pneumoniae and Haemophilus influenzae susceptibilities from community-acquired respiratory tract infections and hospitalized patients with pneumonia: five-year results for the SENTRY Antimicrobial Surveillance Program.
Gordon KA; Biedenbach DJ; Jones RN
Diagn Microbiol Infect Dis; 2003 Aug; 46(4):285-9. PubMed ID: 12944021
[TBL] [Abstract][Full Text] [Related]
42. Fluoroquinolones in respiratory infections.
Klein NC
Semin Respir Infect; 1991 Sep; 6(3):131-5. PubMed ID: 1754733
[TBL] [Abstract][Full Text] [Related]
43. Comparison of the in vitro activity of and pathogen responses to sparfloxacin with those of other agents in the treatment of respiratory tract, urinary tract, and skin and skin-structure infections.
Dowzicky M; Nadler H; Dorr MB; Acusta A; Talbot GH
Clin Ther; 1999 May; 21(5):790-805; discussion 789. PubMed ID: 10397375
[TBL] [Abstract][Full Text] [Related]
44. Sensitivity to sparfloxacin and other antibiotics, of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis strains isolated from adult patients with community-acquired lower respiratory tract infections: a European multicentre study. SPAR Study Group. Surveillance Programme of Antibiotic Resistance.
Richard MP; Aguado AG; Mattina R; Marre R
J Antimicrob Chemother; 1998 Feb; 41(2):207-14. PubMed ID: 9533462
[TBL] [Abstract][Full Text] [Related]
45. Multicenter surveillance of antimicrobial resistance of Streptococcus pyogenes, Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis to 14 oral antibiotics.
Hsueh PR; Huang WK; Shyr JM; Lau YJ; Liu YC; Luh KT
J Formos Med Assoc; 2004 Sep; 103(9):664-70. PubMed ID: 15361938
[TBL] [Abstract][Full Text] [Related]
46. Clinical perspectives on new antimicrobials: focus on fluoroquinolones.
Talan DA
Clin Infect Dis; 2001 Mar; 32 Suppl 1():S64-71. PubMed ID: 11249831
[TBL] [Abstract][Full Text] [Related]
47. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia.
Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):187-93. PubMed ID: 16105563
[TBL] [Abstract][Full Text] [Related]
48. Antimicrobial susceptibility of bacterial pathogens associated with community-acquired respiratory tract infections in Asia: report from the Community-Acquired Respiratory Tract Infection Pathogen Surveillance (CARTIPS) study, 2009-2010.
Wang H; Chen M; Xu Y; Sun H; Yang Q; Hu Y; Cao B; Chu Y; Liu Y; Zhang R; Yu Y; Sun Z; Zhuo C; Ni Y; Hu B; Tan TY; Hsueh PR; Wang JH; Ko WC; Chen YH; Wahjono H
Int J Antimicrob Agents; 2011 Nov; 38(5):376-83. PubMed ID: 21880469
[TBL] [Abstract][Full Text] [Related]
49. Activity of temafloxacin against respiratory pathogens.
Swanson RN; Hardy DJ; Chu DT; Shipkowitz NL; Clement JJ
Antimicrob Agents Chemother; 1991 Mar; 35(3):423-9. PubMed ID: 2039192
[TBL] [Abstract][Full Text] [Related]
50. Diagnosis and treatment of community-acquired and hospital-acquired pneumonia.
Foster MT
Pharmacotherapy; 1993; 13(2 Pt 2):45S-50S. PubMed ID: 8474938
[TBL] [Abstract][Full Text] [Related]
51. Guide to selection of fluoroquinolones in patients with lower respiratory tract infections.
Shams WE; Evans ME
Drugs; 2005; 65(7):949-91. PubMed ID: 15892589
[TBL] [Abstract][Full Text] [Related]
52. In vitro evaluation of sparfloxacin activity and spectrum against 24,940 pathogens isolated in the United States and Canada, the final analysis.
Jones RN; Ballow CH; Schentag JJ; Johnson DM; Deinhart JA
Diagn Microbiol Infect Dis; 1998 May; 31(1):313-25. PubMed ID: 9597392
[TBL] [Abstract][Full Text] [Related]
53. Comparative activity of garenoxacin and other agents by susceptibility and time-kill testing against Staphylococcus aureus, Streptococcus pyogenes and respiratory pathogens.
Noviello S; Ianniello F; Leone S; Esposito S
J Antimicrob Chemother; 2003 Nov; 52(5):869-72. PubMed ID: 14519672
[TBL] [Abstract][Full Text] [Related]
54. A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new respiratory quinolones'.
Blondeau JM
J Antimicrob Chemother; 1999 May; 43 Suppl B():1-11. PubMed ID: 10382869
[TBL] [Abstract][Full Text] [Related]
55. [Antimicrobial susceptibility of community-acquired respiratory tract pathogens isolated from class B hospitals in China during 2013 and 2014].
Sun H; Chen L; Chen X; Jia X; Li N; Liu W; Tong H; Xiang R; Zhang F; Zhao H; Zhang J; Xu Y
Zhonghua Jie He He Hu Xi Za Zhi; 2016 Jan; 39(1):30-7. PubMed ID: 26792053
[TBL] [Abstract][Full Text] [Related]
56. Comparative in vitro potency of gemifloxacin against European respiratory tract pathogens isolated in the Alexander Project.
Marchese A; Debbia EA; Schito GC
J Antimicrob Chemother; 2000 Jul; 46 Suppl T1():11-5. PubMed ID: 10997594
[TBL] [Abstract][Full Text] [Related]
57. A comparison of the activity of ciprofloxacin and levofloxacin with other agents against respiratory tract pathogens.
Wise R; Andrews JM
J Chemother; 1998 Aug; 10(4):276-9. PubMed ID: 9720464
[TBL] [Abstract][Full Text] [Related]
58. The Alexander Project 1996-1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections.
Felmingham D; Grüneberg RN
J Antimicrob Chemother; 2000 Feb; 45(2):191-203. PubMed ID: 10660501
[TBL] [Abstract][Full Text] [Related]
59. BAY 12-8039, a novel fluoroquinolone. Activity against important respiratory tract pathogens.
Biedenbach DJ; Barrett MS; Croco MA; Jones RN
Diagn Microbiol Infect Dis; 1998 Sep; 32(1):45-50. PubMed ID: 9791757
[TBL] [Abstract][Full Text] [Related]
60. [In vitro comparative activity (E test) of sparfloxacin and other 8 antimicrobial agents against bacteria isolated from patients with respiratory infections acquired in the community].
Prado V; Trucco O; Nina A; Salamanca L; Juliet C; Braun S
Rev Med Chil; 1995 Nov; 123(11):1394-1401. PubMed ID: 8733283
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
